Cases

The fashion industry is under increasing scrutiny for its contribution to microplastic pollution, with synthetic textiles like polyester, nylon, and acrylic shedding microfibers during washing that end up in oceans and food chains. Recent studies estimate that a single laundry load can release up to 700,000 microplastic fibers. In early 2026, the EU proposed regulatory measures requiring filtration systems in washing machines and labeling of synthetic garments, while environmental NGOs are calling for outright bans on non-biodegradable synthetics in disposable fashion. Brands like H&M and Zara face pressure to phase out polyester-heavy collections, yet synthetics remain dominant due to cost, durability, and performance benefits. This trial confronts the tension between environmental harm and practical garment functionality, especially in activewear and outerwear where natural fibers often fall short. The decision impacts designers, consumers, regulators, and waste management systems, with implications for material innovation, circular economy models, and global supply chains.

Wearable smart textiles embedded with nanosensors are now capable of monitoring skin hydration, UV exposure, pH levels, and inflammatory markers in real time. Companies like ChronoSkin and DermaWeave market these garments as early-warning systems for eczema flare-ups or melanoma risk. However, dermatologists caution that consumer-grade sensors lack the calibration and validation of medical devices. The FDA has not cleared most of these textiles as diagnostic tools, yet marketing often implies clinical utility. With rising telehealth adoption, patients increasingly rely on such data for self-management, raising concerns about false reassurance or unnecessary anxiety. This trial weighs the potential of wearable technology to democratize skin health monitoring against risks of unvalidated medical claims and data privacy issues.

In 2024–2025, several U.S. museums—including the Baltimore Museum of Art and the Everson Museum—have faced intense scrutiny and backlash after proposing to sell artworks from their collections (deaccessioning) to fund diversity, equity, and inclusion (DEI) programs, staff salaries, and operational costs. Traditionally, the Association of Art Museum Directors (AAMD) strictly limited deaccessioning proceeds to acquiring new art, but it temporarily relaxed these rules during the pandemic. Some institutions now argue that sustaining inclusive staffing and community engagement is as vital as growing collections. Critics, including major donors and art historians, warn that selling masterpieces for operating expenses erodes public trust, commodifies cultural heritage, and sets dangerous precedents. The debate centers on whether museums' missions should prioritize stewardship of physical collections or equitable access and representation. This dilemma forces the arts community to weigh institutional survival against long-standing ethical norms in art conservation and museum practice.

In early 2025, the U.S. Copyright Office reaffirmed that works created entirely by artificial intelligence without human authorship are not eligible for copyright protection. However, the boundary remains contested: if an artist uses AI as a tool—prompting, editing, compositing, or refining outputs—how much human input is required for copyright? Recent cases, such as the denial of registration for Kris Kashtanova's AI-assisted comic 'Zarya of the Dawn' (later partially granted after revision), highlight the legal gray zone. Digital artists increasingly rely on AI for ideation, texture generation, or style transfer, raising questions about originality, labor, and ownership. The outcome affects not only individual creators but also NFT platforms, galleries, and publishers who need clear guidelines for exhibiting and selling AI-influenced works. This trial confronts the evolving definition of authorship in the digital age.

Following controversies like the removal of Sam Durant's 'Scaffold' (2017) and ongoing debates over monuments, cities including Chicago, Los Angeles, and Toronto have adopted policies requiring community input—or even co-design—in public art commissions. In 2025, a proposed sculpture in Brooklyn sparked protest when residents felt excluded from the selection process, despite the artist's national reputation. Advocates argue that public art funded by taxpayers must reflect local identity, history, and values, and that co-creation fosters ownership and reduces backlash. Critics caution that excessive consensus-building may dilute artistic vision, discourage bold conceptual work, or privilege vocal minorities over broader aesthetic considerations. This trial examines whether collaborative processes enhance or compromise the integrity and impact of public art.

In 2025, leading art institutions like the Royal College of Art and Parsons School of Design are integrating generative AI into foundational courses, sparking debate among educators, students, and practicing artists. Proponents argue that fluency in AI tools—such as Midjourney, Stable Diffusion, and Runway ML—is essential for contemporary creative careers in illustration, concept art, and design. Critics worry that prioritizing AI may erode foundational skills in drawing, color theory, and material handling, producing graduates who rely on algorithms rather than developing unique visual languages. The tension reflects a broader question: should art education preserve classical techniques as non-negotiable, or adapt fluidly to technological shifts? This trial examines the balance between tradition and innovation in shaping the next generation of artists.

Despite the 2022–2023 NFT market crash, artists and institutions continue to explore blockchain-based solutions for authenticating and preserving digital art. However, critical challenges persist: link rot (when NFTs point to off-chain image files that disappear), platform obsolescence, and the environmental impact of older proof-of-work blockchains. In 2024, initiatives like the Digital Art Preservation Project and Ethereum's shift to proof-of-stake reignited discussion about whether NFTs can ensure long-term access and provenance. Some artists now embed media directly on-chain or use decentralized storage (IPFS, Arweave), but adoption remains limited. This trial asks whether NFTs, despite their flaws, offer the best available framework for conserving digital artworks—or if alternative models (institutional archives, open standards) are more viable.

Cold plunges, cryotherapy, and cold showers have gained popularity in biohacking and longevity circles, promoted for boosting metabolism, reducing inflammation, and improving insulin sensitivity. Proponents cite studies showing cold-induced activation of brown adipose tissue (BAT), which burns glucose and lipids. However, recent case reports in 2025 highlight risks: arrhythmias in individuals with undiagnosed heart conditions, hypothermia in elderly users, and exacerbation of Raynaud's or autoimmune disorders. While small trials show modest metabolic benefits, long-term safety and efficacy data are lacking. Functional medicine clinics increasingly recommend cold protocols, but mainstream endocrinology groups caution against unsupervised use. Should cold exposure be considered a legitimate metabolic intervention—or a risky wellness trend?

The CDC recommends routine HPV vaccination up to age 26, but since 2018, the FDA has approved Gardasil-9 for adults up to age 45 based on shared clinical decision-making. However, uptake in this older group remains low (<10%), and insurance coverage is inconsistent. New 2025 data shows rising HPV-related oropharyngeal cancers in men aged 30–50, with limited prior exposure to the virus. Some experts argue that expanding routine recommendation—not just shared decision-making—could reduce cancer burden, especially in unvaccinated adults with new sexual partners. Others counter that vaccine efficacy declines with age and prior exposure, making population-level benefit marginal. As cancer rates climb, should guidelines shift to actively recommend vaccination for all adults up to 45, regardless of sexual history?

Following the DEA's temporary pandemic-era rules allowing telehealth prescribing of Schedule II–V controlled substances (e.g., stimulants for ADHD, benzodiazepines for anxiety), a 2025 rule proposal seeks to extend these flexibilities permanently—but with conditions. The debate centers on access versus safety: rural and underserved patients benefit from virtual access to psychiatrists, yet concerns persist about diversion, misdiagnosis, and inadequate physical evaluation. Recent data shows a 300% increase in telehealth ADHD diagnoses since 2020, with some clinics operating on a 'diagnose-and-prescribe' model lacking comprehensive assessment. As the DEA finalizes rules in mid-2025, clinicians must weigh equity against stewardship. Should first-time prescriptions of controlled psychotropics require an in-person visit, or is virtual evaluation sufficient with proper safeguards?